83. アジソン病 [臨床試験数:20,薬物数:42(DrugBank:13),標的遺伝子数:6,標的パスウェイ数:17

Searched query = "Addison disease", "Primary chronic adrenocortical insufficiency", "Autoimmune polyglandular syndrome", "Hypoparathyroidism-Addison-Monilia syndrome", "HAM syndrome", "Schmidt syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
11 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2015-001090-40-GB
(EUCTR)
22/06/201508/04/2015The effects of two brands of hydrocortisone injected intramuscularly into deltoid and thigh musclesAn open label pilot study to investigate the effects of two preparations of hydrocortisone (Hydrocortisone 100mg/ml and Solu-Cortef) injected intramuscularly into the deltoid and upper thigh muscle during the state of hypocortisolaemia - Effects of 100mg Hydrocortisone injection into Deltoid & Thigh Addison's Disease
MedDRA version: 20.1;Level: PT;Classification code 10001130;Term: Addison's disease;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
Trade Name: Solu-Cortef
Product Name: Solu-Cortef
INN or Proposed INN: Hydrocortisone
Trade Name: Hydrocortisone 100mg/ml
Product Name: Hydrocortisone 100mg/ml
INN or Proposed INN: Hydrocortisone
The London ClinicNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
8Phase 4United Kingdom
2EUCTR2012-001104-37-GB
(EUCTR)
06/10/201424/07/2014pulses studyPulsed glucocorticoid replacement therapy for patients with adrenocortical insufficiency secondary to Addison’s disease and congenital adrenal hyperplasia - the pulses study Addison's disease and Congenital Adrenal Hyperplasia
MedDRA version: 17.0;Level: LLT;Classification code 10011195;Term: Cortisol;System Organ Class: 100000004848
MedDRA version: 17.0;Classification code 10020518;Term: Hydrocortisone;System Organ Class: 100000004848;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: hydrocortisone sodium phosphate
Product Name: hydrocortisone sodium phosphate
INN or Proposed INN: hydrocortisone sodium phosphate
Trade Name: hydrocortisone
Product Name: hydrocortisone
INN or Proposed INN: hydrocortisone
University Hospitals Bristol NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
United Kingdom
3NCT02096510
(ClinicalTrials.gov)
August 201428/11/2013Ultradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal HyperplasiaUltradian Subcutaneous Hydrocortisone Infusion in Addison Disease and Congenital Adrenal HyperplasiaAddison Disease;Adrenal Hyperplasia CongenitalDrug: Solu-Cortef;Drug: CortefHaukeland University HospitalNULLRecruiting18 Years65 YearsBoth10Phase 1/Phase 2Norway
4NCT02152553
(ClinicalTrials.gov)
May 201412/5/2014Biomarker(s) for GlucocorticoidsProtein/Metabolite Biomarker(s) for Glucocorticoid Action; an Experimental Trial in Patients With Adrenal InsufficiencyAddison DiseaseDrug: Hydrocortisone;Drug: PlaceboVastra Gotaland RegionNULLCompleted20 Years60 YearsAll11N/ASweden
5EUCTR2013-004189-33-NO
(EUCTR)
28/11/201330/10/2013A trial comparing continuous subcutaneous hydrocortisone therapy with pulsatile subcutaneous hydrocortisone therapy in patients with Addison`s diseaseULTRADIAN SUBCUTANEOUS HYDROCORTISONE (USHI) INFUSION IN ADDISON’S DISEASE Addison`s disease;Therapeutic area: Diseases [C] - Hormonal diseases [C19]Trade Name: Solu-Cortef
Trade Name: Cortef 5 mg
Haukeland University HospitalNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
10Norway
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01847690
(ClinicalTrials.gov)
June 201323/4/2013Effect of Cortisol on Physical Exertion in Patients With Primary Adrenal FailureEffect of Cortisol on Physical Exertion in Patients With Primary AdrenalAddison DiseaseDrug: HydrocortisoneHaukeland University HospitalNULLActive, not recruiting18 Years70 YearsFemale20Phase 2Norway
7EUCTR2011-002687-25-DE
(EUCTR)
16/11/201106/10/2011Evaluation of the time to cortisol levels required in critical illness (>1000 nmol/l) and safety of hydrocortisone, after subcutaneous injection in patients with chronic primary adrenal insufficiency(Comparison s.c. vs. i.m.)Pharmacokinetics of Hydrocortisone after Subcutaneous Administration Compared with Intramuscular Injection in Chronic Adrenal Insufficiency(PHYSCA-Trial) - PHYSCA- Trial Adrenal insufficiency under chronic glucocorticoid replacement
MedDRA version: 14.0;Level: PT;Classification code 10001130;Term: Addison's disease;System Organ Class: 10014698 - Endocrine disorders
MedDRA version: 14.0;Classification code 10052381;Term: Primary adrenal insufficiency;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
Trade Name: Hydrocortison 100 mg (Pfizer®) in 2 ml solvent
INN or Proposed INN: Hydrocortisone
Other descriptive name: HYDROCORTISONE HYDROGEN SUCCINATE
University Hospital of WuerzburgNULLNot RecruitingFemale: yes
Male: yes
12Germany
8EUCTR2009-010917-61-SE
(EUCTR)
25/08/201005/07/2010Glucocorticoid Replacement in Addison's diseaseGlucocorticoid Replacement in Addison's disease Autoimmune Addison's disease is a rare and chronic disease wich leads to primary adrenal failure. The conventional glucocorticoid replacement therapy in primary adrenal insufficiency (Addison’s disease) renders the cortisol levels unphysiological, which may cause symptoms and long-term complications. In this study we will include patients with Addison's disease to explore if more physiological glucocorticoid treatment could improve health for the patients.
MedDRA version: 9.1;Level: LLT;Classification code 10001130;Term: Addison's disease
Trade Name: Solu-Cortef
INN or Proposed INN: HYDROCORTISONE SODIUM SUCCINATE
Product Name: Hydrokortison APL kapsel 2,5 mg
INN or Proposed INN: Hydrocortisonum
Haukeland University hospitalNULLNot RecruitingFemale: yes
Male: yes
40Sweden
9EUCTR2007-005170-30-FR
(EUCTR)
08/12/200725/10/2007Pharmacocinétique de l’Hydrocortisone chez le patient ADdisonien : évaluation de la valeur prédictive de l’ACTH plasmatique pour la titration du traitement substitutif - PHADPharmacocinétique de l’Hydrocortisone chez le patient ADdisonien : évaluation de la valeur prédictive de l’ACTH plasmatique pour la titration du traitement substitutif - PHAD ADDISON'S DISEASE
MedDRA version: 9.1;Level: LLT;Classification code 10001130;Term: Addison's disease
Trade Name: hydrocortisone Roussel
Product Name: HYDROCORTISONE ROUSSEL
CHU CAENNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
10EUCTR2005-001768-30-SE
(EUCTR)
04/01/200607/12/2005Comparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life. - CHEQComparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life. - CHEQ We aim to study patients with cortisol deficiency caused by primary adrenal insufficiency (Addison’s disease of autoimmune origin). Product Name: HydrocortisoneEM-klinikenNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
12Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00688987
(ClinicalTrials.gov)
August 200030/5/2008The Hypothalamic-Pituitary-Adrenal (HPA) Axis as an Effector System in Weight RegulationCortisol, Central Obesity, and Insulin Resistance: Long Term Studies in Addison's PatientsObesity;Addison's DiseaseDrug: Hydrocortisone;Dietary Supplement: Isocaloric DietOregon Health and Science UniversityNULLCompleted18 YearsN/ABoth24N/AUnited States